Monday
Problem Mapping
Define the long-term goal for Curodont at SGA, map the problem across all stakeholders, identify where the system breaks, and select sprint targets.
Network Opportunity
$7.5M
Annual gross at 50% adoption (130 practices)
Margin Gap
2-3x
Hygienist margin vs. doctor margin per treatment
Provider Split
75/25
Doctor/Hygienist (should be inverted)
D2991 Denial Rate
~70-85%
CDT 2024 code — mirrors D4346 in 2017
Key Legal Finding
Colorado SB17-190 Protects Full UCR Collection
Colorado law (2017) prohibits dental plans from dictating fees for non-covered services. Collecting $120 upfront for D2991 is NOT balance billing — it's charging UCR for a truly non-covered service. Legal in 44 states.
Competitive Signal
Aspen Dental (1,000+ Locations) Adopted Curodont
Aspen partnered with vVardis in Feb 2025. Henry Schein became exclusive US distributor Sept 2024. SGA must standardize before competitors establish the playbook.
Long-Term Goal
In 18 months, SGA will standardize Curodont delivery across 260+ practices with hygienist-led placement (75%+), a sustainable pricing model that maintains $80+ DSO net margin per treatment, and a billing strategy that protects cash flow during the 2-3 year D2991 insurance adoption window — generating $5M+ in annual DSO net revenue.
Goal Validation
Passed
- Ambitious enough? $5M+ DSO net across 260 practices is transformational for a single product line
- Specific enough? Provider split %, margin floor, revenue target, timeline for insurance adoption
- Believable? $120 UCR with $28 cost = 76.7% margin (hygienist). Math works if placement shifts.
- Inspires? Doesn't prescribe a single billing strategy; opens multiple pathways
The Core Insight
Curodont is a $92 net margin product when placed by a hygienist (3-5 min added chair time, $18-31/min revenue). When a doctor places it, the 30% commission drops net to $56, and it consumes 8-12 minutes of chair time worth $400-600/hour in restorative production. The pricing debate is a symptom — the real problem is who holds the applicator.
Sprint Questions
What Could Kill the Curodont Rollout?
Assume the rollout failed in 18 months. What went wrong?
SQ1 — Highest Risk
Can we shift Curodont placement from 75% doctor / 25% hygienist to 25/75 when doctors earn 30% commission on each placement and have no financial incentive to let go?
SQ2 — High Risk
Can we maintain $120 UCR and protect cash flow when D2991 has a 70-85% insurance denial rate and RCM is too small to chase claims — without resorting to non-compliant billing practices?
SQ3
Will doctors accept a standardized $120 fee without a sliding scale — or will frustration from clinical presidents undermine network-wide adoption?
SQ4
Can we build a reliable payer reimbursement database across 260 practices fast enough to inform pricing strategy before the clinical presidents lose patience?
SQ5
Can we standardize Curodont case presentation, morning huddle identification, and patient consent across 260 practices with no centralized hygiene leadership layer?
Problem Map
The Curodont Treatment Journey
Left to right: actors, journey steps, and goal. Amber steps mark critical moments where the system breaks.
Patient
Arrive for Hygiene
→
Learn About Curodont
→
Hear Price ($120)
→
Accept / Decline
→
Pay at Checkout
Curodont
Standard of Care
75%+ Hygienist
$120 UCR
$5M+ DSO Net
Standard of Care
75%+ Hygienist
$120 UCR
$5M+ DSO Net
Hygienist
Review Chart
→
ID Candidate
→
Present to Patient
→
Apply Curodont (3-5 min)
→
Document D2991
Doctor
Release to Hygiene?
→
-
→
-
→
Exam / Confirm Tx
→
30% Commission?
Front Desk
Collect $120 Upfront
→
Consent Form
→
Enter D2991 in PMS
→
-
→
-
RCM Team
Generate Claim
→
Submit D2991
→
ERA Processing
→
Paid / Denied?
→
Refund or Write-off
DSO Leadership
Set UCR / Policy
→
Train Network
→
Monitor Margins
→
Negotiate w/ Payers
→
Scale or Kill
Critical Moments
Where the System Breaks
| # | Moment | Actor | Why It's Critical |
|---|---|---|---|
| ★1 | Doctor Won't Release to Hygiene | Doctor | 30% commission = $36/placement. Releasing to hygienist = $0. No financial incentive to shift. This is the #1 blocker. |
| ★2 | Insurance Denies D2991 | RCM | 70-85% denial rate. New CDT code (2023). Many payers don't have it in their fee schedule. Same trajectory as D4346 in 2017. |
| ★3 | Balance Billing Compliance | RCM / Legal | Collecting $120 upfront then submitting to insurance may violate PPO contracts. Non-covered waiver doesn't protect from billing obligation. |
| ★4 | Price Objection at Chair | Patient | $120 feels high for a "gel application." Without insurance coverage certainty, case acceptance drops. Need strong value narrative. |
| ★5 | Inconsistent Pricing | Front Desk | Before RCM standardized, practices charged wildly different amounts. Sliding scale requests reintroduce inconsistency. |
| ★6 | Candidate Identification | Hygienist | Without morning huddle protocol and calibration, hygienists don't know which patients to present Curodont to. |
| ★7 | No Payer Data | DSO Leadership | RCM says D2991 is "too new" for reimbursement data. Can't make informed pricing decisions without building the database. |
| ★8 | RCM Capacity | RCM | Team too small to chase unpaid D2991 claims. Collect-upfront model essential but creates its own compliance questions. |
| ★9 | Clinical President Frustration | Doctors | The champions who drive adoption are frustrated by $120 price and lack of insurance clarity. Losing them = losing the rollout. |
How Might We
22 Opportunity Notes
Grouped by theme. Each HMW is an opportunity space, not a solution.
A. Provider Economics & Compensation 5
HMW restructure doctor compensation so they don't lose income when Curodont shifts to the hygiene chair?
HMW make hygienist-placed Curodont more attractive than doctor-placed Curodont without creating resentment?
HMW introduce a small hygienist incentive ($5-10/placement) that drives adoption without adding comp complexity?
HMW align doctor production targets to exclude Curodont revenue that shifts to hygiene?
HMW frame the conversation with doctors as "you gain restorative chair time" rather than "you lose $36/placement"?
B. Insurance Billing & Compliance 5
HMW collect full fee upfront without violating PPO contract balance billing restrictions?
HMW build a payer reimbursement database across 260 practices when RCM says the code is "too new"?
HMW use SGA's 260-practice claim volume to accelerate D2991 payer adoption (D4346 took 3 years)?
HMW create an appeal process for D2991 denials that doesn't overwhelm our small RCM team?
HMW treat D2991 billing like any other code instead of inventing special processes that create compliance risk?
C. Pricing Strategy 4
HMW maintain a $120 UCR that keeps insurance payers recognizing the procedure's value while doctors push for lower prices?
HMW design a sliding scale (if needed) that doesn't drop below the $80 hygienist / $90 doctor margin floor?
HMW position $120 as a value ("avoid a $300+ filling") rather than a cost?
HMW price Curodont competitively against alternatives (fluoride varnish $30-45, SDF $25-40, fillings $200-400)?
D. Clinical Workflow & Adoption 4
HMW integrate Curodont into the standard hygiene workflow when 3 of 5 application steps are already in the prophy protocol?
HMW add Curodont candidate identification to the morning huddle without adding huddle time?
HMW train hygienists on case presentation for Curodont when they already present fluoride and sealants?
HMW achieve 1-2 placements/day per practice (target) when 25-35% of hygiene patients are candidates?
E. Stakeholder Management 2
HMW keep clinical presidents engaged as Curodont champions when their pricing and insurance concerns haven't been resolved?
HMW present data-driven decisions to the clinical presidents fast enough to maintain their trust?
F. Vendor & Market Position 2
HMW leverage SGA's 260-practice scale to negotiate better Vivardis pricing if insurance reimbursement stays low?
HMW evaluate whether "the juice is worth the squeeze" if payers consistently reimburse at $45-50?
Expert Analysis
What the Evidence Says
⚙ Insurance & Coding Analysis
- D2991 is CDT 2024: "Application of hydroxyapatite regeneration medicament, per tooth." Classified Restorative (D2000 series).
- D4346 precedent: Added 2017, took 3 years for majority payer acceptance. D2991 is on the same ~2027-2028 trajectory.
- Colorado SB17-190: Dentists CAN charge full UCR for non-covered services. Collecting $120 upfront is NOT balance billing.
- Must still submit claims. Non-covered waiver does NOT eliminate billing obligation. Always submit D2991 to build payer data.
- Option B is the compliant model: Collect $120 upfront, submit claim with K02.61 narrative, refund if insurance pays.
- Known coverage: United Concordia (ages 1-6), Delta Dental MI (published criteria). Most major payers still building policies.
- Never code as D9910 or D1208 — miscoding = False Claims Act exposure. D9999 is valid fallback if payer rejects D2991.
- Appeal every denial. 260-practice claim volume accelerates payer adoption by 12-18 months vs. individual practices.
💰 Financial Model
- At $120 UCR: Hygienist net = $92.00 (76.7%). Doctor net = $56.00 (46.7%) after 30% commission.
- Break-even: Hygienist at $28 (just product cost). Doctor at $40 (product + commission).
- Brittney's floors are too low: $40 hygienist / $55 doctor leave thin margins. Recommend $80 / $90 minimum.
- Revenue per minute: $18-31/min in hygiene chair — highest of all hygiene add-ons (beats fluoride, sealants, SDF).
- Network opportunity at 50% adoption: $7.5M gross, $4.7-5.8M DSO net depending on provider mix.
- Provider shift impact: Moving from 75/25 doctor/hygienist to 25/75 adds ~$2.7M/year to DSO net margin.
👤 Practice Operations
- Net new chair time: 3-5 min in hygiene (steps 1, 2, 5 already happen). 8-12 min in doctor chair (must duplicate).
- Chair time economics: Doctor chair = $400-600/hr opportunity cost. Hygiene = $180-250/hr. 2-3x margin difference.
- 25-35% of hygiene patients are Curodont candidates (moderate/high caries risk with incipient lesions).
- Target: 1-2 placements/day per practice, building to 2-3. Monthly target: 20-40 placements/practice.
- Case acceptance framework: "Treat the cavity without drilling" + "$120 vs. $300+ filling" value narrative.
- Morning huddle: Flag patients with caries history, white spots, incipient lesions on BWX, high CRA scores.
★ Compensation & Behavior
- The real blocker is money: Doctors earn $36/placement (30% of $120). Releasing to hygienist = $0. Price objections are a proxy.
- Best fix: Adjust doctor production targets to exclude shifted Curodont + add small hygienist placement bonus ($5-10).
- Doctor frustration is disingenuous (Brittney's word): They could solve the patient cost problem by letting hygienists place it.
- NC Board precedent (Oct 2024): NC explicitly ruled hygienists can place Curodont under dentist supervision. Other states will follow.
- Consider flat doctor fee: $15-20/application instead of 30% commission. Minimal chair time doesn't justify full commission.
💻 Technology & Systems
- Dental Intel (95% adoption) is the fastest path to D2991 data — can pull production by code, provider, and practice TODAY.
- NexHealth does NOT expose financial data. Appointments and procedure codes only. No fees, ERA results, or write-offs.
- Automated narrative template: Push a standard D2991 clinical narrative into all PMS procedure code settings (same method RCM used for UCR).
- Clearinghouse flagging: Configure rules to auto-flag D2991 ERAs and build the reimbursement database passively.
- Phase A safe: D2991 reimbursement database is aggregate data (payer + practice + amount) with no patient identifiers.
- Power BI dashboard: Dental Intel → ClickHouse → Power BI = D2991 executive visibility without building new infrastructure.
🏆 Competitive Landscape
- Aspen Dental (1,000+ locations) partnered with vVardis Feb 2025 — Curodont is already being deployed at DSO scale.
- Henry Schein exclusive distributor (Jan 2026, all US segments) — SGA's existing supply chain handles procurement.
- Curodont competitors: CrystLCare (Greenmark) is the only direct D2991 competitor. MI Paste, Clinpro, SDF are different mechanisms.
- DSO rollout failure rate: 60-70% due to training/workflow gaps, not product issues. Structured onboarding = 2-3x faster adoption.
- Industry UCR norm: 4-6x material cost. $120 on $28 cost = 4.3x (reasonable). $120 on $38 cost = 3.2x (below norm).
Financial Model
Margin by Price Point & Provider
Product cost: $28.00/unit (per Brittney). Note: some distributors list $38/unit — verify with procurement. Doctor commission: 30%. Hygienist commission: $0.
| UCR Fee | Hygienist Net | Hygienist % | Doctor Net | Doctor % | Blended 75/25 Dr/Hyg | Blended 25/75 Dr/Hyg |
|---|---|---|---|---|---|---|
| $40 | $12.00 | 30.0% | $0.00 | 0.0% | $3.00 | $9.00 |
| $55 | $27.00 | 49.1% | $10.50 | 19.1% | $14.63 | $22.88 |
| $80 | $52.00 | 65.0% | $28.00 | 35.0% | $34.00 | $46.00 |
| $90 | $62.00 | 68.9% | $35.00 | 38.9% | $41.75 | $55.25 |
| $100 | $72.00 | 72.0% | $42.00 | 42.0% | $49.50 | $64.50 |
| $120 | $92.00 | 76.7% | $56.00 | 46.7% | $65.00 | $83.00 |
| $150 | $122.00 | 81.3% | $77.00 | 51.3% | $88.25 | $110.75 |
Target Selection
Sprint Focus: A+B
The sprint will tackle Provider Economics and Insurance Billing simultaneously — they're interdependent. Pricing strategy follows from both.
Target A: Provider Economics & Placement Shift
Selected
Restructure compensation to eliminate the financial barrier keeping doctors from releasing Curodont to hygienists. This is the single highest-impact lever: shifting from 75/25 to 25/75 adds $2.7M/year in DSO net margin and makes lower price points viable.
24/25
Target B: Insurance Billing Strategy & Compliance
Selected
Define a compliant billing workflow (Option B: collect upfront, submit, refund) with standardized narrative, denial appeal process, and centralized payer tracking. Resolve the balance billing question definitively.
23/25
Target C: Clinical Workflow & Network Adoption
Parked
Standardize morning huddle protocols, hygienist training, and case presentation scripts. Strong playbook exists from the operations analysis — but execution depends on solving A and B first.
20/25
Tuesday
Solution Sketching
Five distinct approaches to solving the provider economics and insurance billing challenges for Curodont across 260 practices.
Coming Tomorrow
Tuesday's solution sketches will present 5 genuinely different approaches to the provider shift + billing strategy challenge, with cross-industry inspiration, pros/cons, and a comparison matrix.
Wednesday
Decision
Structured decision matrix, hybrid recommendation, and implementation storyboard.
Pending Tuesday Solutions
Wednesday's decision will score all solutions against sprint questions, select the winning approach, and map the implementation storyboard step by step.
Thursday
Prototype
Operational playbook, billing workflows, patient forms, and staff scripts.
Pending Wednesday Decision
Thursday's prototype will build the operational playbook: pricing tiers, billing SOPs, consent forms, RCM workflows, hygienist training materials, and morning huddle protocols.
Friday
Test & Validate
Pilot program design, KPI tracking framework, and executive summary.
Pending Thursday Prototype
Friday will design the pilot program (10-15 practices), define success metrics, build the risk register, and produce the executive summary for leadership presentation.